AR060332A1 - Anticuerpo terapeutico que se une al peptido beta-amiloide, composicion farmaceutica que lo comprende y su uso para preparar un medicamento - Google Patents

Anticuerpo terapeutico que se une al peptido beta-amiloide, composicion farmaceutica que lo comprende y su uso para preparar un medicamento

Info

Publication number
AR060332A1
AR060332A1 ARP070101295A ARP070101295A AR060332A1 AR 060332 A1 AR060332 A1 AR 060332A1 AR P070101295 A ARP070101295 A AR P070101295A AR P070101295 A ARP070101295 A AR P070101295A AR 060332 A1 AR060332 A1 AR 060332A1
Authority
AR
Argentina
Prior art keywords
seq
beta
amyloid peptide
prepare
pharmaceutical composition
Prior art date
Application number
ARP070101295A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR060332A1 publication Critical patent/AR060332A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Anticuerpo terapéutico que es un anticuerpo o fragmento de union a antígeno y/o derivado del mismo que se une al péptido beta-amiloide y que comprende las siguientes CDR: CDRH1: DNGMA (SEC ID N°: 1); CDRH2: FISNLAYSIDYADTVTG (SEC ID N°: 2); CDRH3: GTWFAY (SEC ID N°: 3); dentro de una region variable de cadena pesada humana procedente de la familia génica VH3 y CDRL1: RVSQSLLHSNGYTYLH (SEC 1D N°: 4) CDRL2: KVSNRFS (SEC ID N°: 5) CDRL3: SQTRHVPYT (SEC ID N°: 6) dentro, de una region variable de cadena ligera humana procedente de la secuencia de aminoácidos descrita en GenPept con la entrada CAA51 135 (SEC ID N°: 24). La region variable de cadena pesada humana procede de un gen V seleccionado entre la siguiente subserie de miembros de la familia VH3: VH3-48, VH3-21, VH3-11, VH3-7, VH3-13, VH3-74, VH3-64, VH3-23, VH3-38, VH3-53, VH3-66, VH3-20, VH3-9 y VH3-43; un gen V seleccionado entre la siguiente subserie de miembros de la familia VH3: VH3-48, VH3-21 y VH3-11; el gen VH3-48 o un alelo de los mismos. La region flanqueante de cadena pesada aceptora humana procede de M99675 (SEC ID N°: 21) junto con una region flanqueante. Composicion farmacéutica que lo comprende y uso del mismo para preparar un medicamento util para el tratamiento de una enfermedad relacionada con el péptido beta-amiloide, particularmente a enfermedad de Alzheimer.
ARP070101295A 2006-03-30 2007-03-28 Anticuerpo terapeutico que se une al peptido beta-amiloide, composicion farmaceutica que lo comprende y su uso para preparar un medicamento AR060332A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78758806P 2006-03-30 2006-03-30

Publications (1)

Publication Number Publication Date
AR060332A1 true AR060332A1 (es) 2008-06-11

Family

ID=38284050

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101295A AR060332A1 (es) 2006-03-30 2007-03-28 Anticuerpo terapeutico que se une al peptido beta-amiloide, composicion farmaceutica que lo comprende y su uso para preparar un medicamento

Country Status (33)

Country Link
US (3) US8227576B2 (es)
EP (2) EP2177536B1 (es)
JP (1) JP5103466B2 (es)
KR (2) KR101263294B1 (es)
CN (2) CN101415729B (es)
AR (1) AR060332A1 (es)
AT (1) ATE451392T1 (es)
AU (1) AU2007233831B2 (es)
BR (1) BRPI0709246A2 (es)
CA (1) CA2647808C (es)
CR (1) CR10347A (es)
CY (1) CY1109877T1 (es)
DE (1) DE602007003703D1 (es)
DK (2) DK2177536T3 (es)
EA (1) EA015654B9 (es)
ES (2) ES2484967T3 (es)
HK (2) HK1138015A1 (es)
HR (2) HRP20100115T1 (es)
IL (1) IL193695A (es)
JO (1) JO2576B1 (es)
MA (1) MA30337B1 (es)
MX (1) MX2008012483A (es)
MY (1) MY149630A (es)
NO (1) NO20083793L (es)
NZ (1) NZ571038A (es)
PE (1) PE20080181A1 (es)
PL (2) PL1996621T3 (es)
PT (2) PT1996621E (es)
SI (2) SI2177536T1 (es)
TW (1) TWI385179B (es)
UA (1) UA94734C2 (es)
WO (1) WO2007113172A2 (es)
ZA (1) ZA200807911B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
CN102775472A (zh) 2003-01-06 2012-11-14 安吉奥开米公司 作为穿过血脑屏障的载体的抑酶肽及类似物
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
AU2006208226A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
KR101434935B1 (ko) 2005-11-30 2014-10-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의용도
JP5475994B2 (ja) 2005-11-30 2014-04-16 アッヴィ・インコーポレイテッド 抗Ａβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
KR101605207B1 (ko) 2006-07-14 2016-03-22 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US7931899B2 (en) 2007-05-14 2011-04-26 Medtronic, Inc Humanized anti-amyloid beta antibodies
US8323654B2 (en) 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
PL2182983T3 (pl) * 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
CN101848936B (zh) 2007-08-20 2017-05-03 葛兰素集团有限公司 生产方法
GB0718737D0 (en) * 2007-09-25 2007-11-07 Glaxo Group Ltd Antibodies
SG185277A1 (en) * 2007-10-05 2012-11-29 Genentech Inc Humanized antibody
CN101883790B (zh) 2007-10-05 2015-09-09 基因技术公司 抗淀粉样蛋白β抗体在眼病中的用途
HUE039950T2 (hu) * 2007-10-12 2019-02-28 Hoffmann La Roche Fehérjeexpresszió több nukleinsavból
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2222700A2 (en) * 2007-11-27 2010-09-01 Medtronic, Inc. Humanized anti-amyloid beta antibodies
MX2010006422A (es) * 2007-12-11 2010-06-25 Glaxo Group Ltd Proteinas de union a antigenos.
CA2709354C (en) 2007-12-21 2014-06-17 Amgen Inc. Anti-amyloid antibodies and uses thereof
PE20091882A1 (es) 2008-05-06 2009-12-24 Glaxo Group Ltd Encapsulacion de agentes biologicamente activos
EP2346906A4 (en) 2008-10-15 2013-04-24 Angiochem Inc CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
JP5759379B2 (ja) 2008-12-05 2015-08-05 アンジオケム インコーポレーテッド ニューロテンシンまたはニューロテンシンアナログおよびその使用
CA2759129C (en) 2009-04-20 2018-12-11 Angiochem Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
WO2011000095A1 (en) * 2009-07-02 2011-01-06 Angiochem Inc. Multimeric peptide conjugates and uses thereof
EA022007B1 (ru) 2009-09-11 2015-10-30 Пробиодруг Аг Гетероциклические производные в качестве ингибиторов глутаминилциклазы
EP2308897A1 (en) * 2009-10-09 2011-04-13 Pierre Fabre Medicament Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
EP2542579A1 (en) 2010-03-03 2013-01-09 Boehringer Ingelheim International GmbH Biparatopic abeta binding polypeptides
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
WO2011149461A1 (en) * 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
AU2011282536B2 (en) 2010-07-30 2015-12-24 Ac Immune S.A. Safe and functional humanized anti beta-amyloid antibody
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
NZ706751A (en) * 2010-11-30 2016-10-28 Genentech Inc Low affinity blood brain barrier receptor antibodies and uses therefor
EP2670434B1 (en) 2011-01-31 2018-12-26 Tau Bio-Logic Corp. Treatment of tauopathies
BR112013027224A8 (pt) 2011-04-22 2018-08-14 Emergent Product Dev Seattle Proteínas de ligação de antígeno de membrana específico de próstata e composições e métodos relacionados
GB201113570D0 (en) * 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
CN108992668B (zh) 2012-05-21 2023-12-05 霍夫曼-拉罗奇有限公司 用于提高血脑屏障转运的安全性的方法
RU2509155C1 (ru) * 2012-10-25 2014-03-10 Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии
WO2014203188A2 (en) 2013-06-19 2014-12-24 Glaxosmithkline Intellectual Property (No.2) Limited Novel assay
CN104558172A (zh) * 2015-01-04 2015-04-29 东南大学 一种针对β淀粉样蛋白的单域重链纳米抗体及其应用
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
JP7002446B2 (ja) 2015-09-21 2022-03-04 アプティーボ リサーチ アンド デベロップメント エルエルシー Ｃｄ３結合ポリペプチド
WO2017072090A1 (en) * 2015-10-27 2017-05-04 Glaxosmithkline Intellectual Property Development Limited Combination therapy
EP3624842A4 (en) 2017-06-29 2021-04-07 The Trustees Of Columbia University In The City Of New York CHIMERA ANTIBODIES FOR TREATMENT OF AMYLOID DEPOSITION DISEASES
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
AU2019304384A1 (en) * 2018-07-17 2021-01-28 Jiangsu Hengrui Medicine Co., Ltd. Anti-abeta antibody, antigen-binding fragment thereof and application thereof
CN113874078A (zh) 2019-04-05 2021-12-31 Tauc3生物制品有限公司 抗tauc3抗体及其应用
US20220049009A1 (en) 2020-07-23 2022-02-17 Othair Prothena Limited Anti-Abeta Antibodies
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CN114591918B (zh) * 2022-05-07 2022-07-26 北京第一生物化学药业有限公司 产生抗β-淀粉样蛋白抗体的杂交瘤细胞及其用途
CN114591917B (zh) * 2022-05-07 2022-09-02 北京第一生物化学药业有限公司 产生结合β-淀粉样蛋白的抗体的杂交瘤细胞及其用途
KR102530956B1 (ko) * 2022-09-08 2023-05-11 주식회사 알츠코리아 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도
CN118638219A (zh) * 2024-08-19 2024-09-13 成都迈科康生物科技有限公司 一种抗轮状病毒vp8蛋白的抗体或其抗原结合片段、抗体偶联物、核酸、载体、细胞及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869262A (en) * 1992-01-27 1999-02-09 Icos Corporation Method for monitoring an inflammatory disease state by detecting circulating ICAM-R
EP2305709A1 (en) * 1997-04-09 2011-04-06 Intellect Neurosciences, Inc. Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods for use thereof
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
AU1742200A (en) * 1998-11-25 2000-06-13 Eli Lilly And Company Prevention and treatment of amyloid-associated disorders
DE1257584T1 (de) * 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
AU2002239766B9 (en) * 2000-11-03 2007-04-05 The J. David Gladstone Institutes Methods of treating disorders related to apoE
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
ITTO20020867A1 (it) * 2002-10-08 2004-04-09 Pro Cord Spa Schienale di sedia.
JP2006519762A (ja) * 2002-10-09 2006-08-31 ライナット ニューロサイエンス コーポレイション アミロイドβペプチド及びその組成物に対する抗体を使用して、アルツハイマー病を治療する方法

Also Published As

Publication number Publication date
JP5103466B2 (ja) 2012-12-19
PL2177536T3 (pl) 2014-11-28
EA200801842A1 (ru) 2009-02-27
WO2007113172A2 (en) 2007-10-11
HK1138015A1 (en) 2010-08-13
PT1996621E (pt) 2010-03-08
MX2008012483A (es) 2008-10-10
US20160024197A1 (en) 2016-01-28
US20110142824A1 (en) 2011-06-16
HK1122311A1 (en) 2009-05-15
CA2647808C (en) 2015-11-17
UA94734C2 (ru) 2011-06-10
US20140050719A1 (en) 2014-02-20
MY149630A (en) 2013-09-13
PL1996621T3 (pl) 2010-05-31
TW200815466A (en) 2008-04-01
EP2177536B1 (en) 2014-06-04
NZ571038A (en) 2011-03-31
SI1996621T1 (sl) 2010-04-30
CA2647808A1 (en) 2007-10-11
KR101263294B1 (ko) 2013-06-04
CR10347A (es) 2008-10-29
CN101415729B (zh) 2013-09-04
PT2177536E (pt) 2014-08-22
CY1109877T1 (el) 2014-09-10
EP2177536A1 (en) 2010-04-21
ES2484967T3 (es) 2014-08-12
KR20120093400A (ko) 2012-08-22
DK2177536T3 (da) 2014-07-14
EP1996621B1 (en) 2009-12-09
DK1996621T3 (da) 2010-04-19
EP1996621A2 (en) 2008-12-03
HRP20140618T1 (hr) 2014-08-15
AU2007233831A1 (en) 2007-10-11
ZA200807911B (en) 2009-11-25
HRP20100115T1 (hr) 2010-04-30
IL193695A0 (en) 2011-08-01
ATE451392T1 (de) 2009-12-15
DE602007003703D1 (de) 2010-01-21
BRPI0709246A2 (pt) 2011-07-12
PE20080181A1 (es) 2008-03-16
ES2338179T3 (es) 2010-05-04
US9193784B2 (en) 2015-11-24
AU2007233831B2 (en) 2013-02-14
EA015654B1 (ru) 2011-10-31
TWI385179B (zh) 2013-02-11
SI2177536T1 (sl) 2014-09-30
CN103539857A (zh) 2014-01-29
JO2576B1 (en) 2011-02-27
MA30337B1 (fr) 2009-04-01
US8227576B2 (en) 2012-07-24
WO2007113172A3 (en) 2007-11-29
KR20080113273A (ko) 2008-12-29
CN101415729A (zh) 2009-04-22
IL193695A (en) 2012-05-31
NO20083793L (no) 2008-10-13
EA015654B9 (ru) 2012-01-30
JP2009531380A (ja) 2009-09-03

Similar Documents

Publication Publication Date Title
AR060332A1 (es) Anticuerpo terapeutico que se une al peptido beta-amiloide, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
CA2993423C (en) Il-8-binding antibodies and uses thereof
RU2563830C2 (ru) Лечение остеоартрита и боли
AU2006325860B2 (en) Anti-IL-17 antibodies
ES2657292T3 (es) Anticuerpos anti-miostatina
DK2260055T3 (en) Monoclonal antibodies against RGM A protein and uses thereof
AU2018254600A1 (en) TREM2 antigen binding proteins and uses thereof
CN110662770A (zh) 结合凝血因子ix和凝血因子x的双特异性抗体
PE20090518A1 (es) Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)
KR20110031152A (ko) Ｉｌ-６에 대한 항체 및 그의 용도
RU2721706C2 (ru) Нейтрализующие связывающие молекулы, направленные против вируса гриппа, и пути их применения
JP2016028084A (ja) 抗原結合性タンパク質
PE20130040A1 (es) Proteinas de union a antigeno
US11891435B2 (en) Polynucleotides encoding monoclonal antibodies binding to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) and methods of making thereof
KR20200040903A (ko) 기분 장애의 치료 및 진단을 위한 항-서열 유사성 19를 가진 패밀리, 멤버 a5 항체의 용도
JPWO2019230856A1 (ja) Ｎａｖ１．７モノクローナル抗体
WO2022052733A1 (zh) 针对SARS-CoV-2的无ADE效应的中和抗体
EP3883607A2 (en) Safe and effective method of treating psoriasis with anti-il-23 specific antibody
KR20210022065A (ko) 암을 치료하는 데 사용하기 위한 lif 억제제와 백금-기반 항신생물제의 조합

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee